Form 4: Anika CEO Griffin Reports Stock Vesting, Tax Withholding

Anika Therapeutics CEO Stephen D. Griffin reported the vesting of restricted stock units and performance stock units, alongside shares withheld for tax obligations.

Summary

• Stephen D. Griffin, President and CEO of Anika Therapeutics, Inc. (ANIK), reported transactions involving common stock and derivative securities.
• On March 14, 2026, 12,824 shares of common stock were acquired upon the vesting and conversion of restricted stock units (RSUs).
• An additional 6,412 shares of common stock were acquired, representing the first vesting installment of performance-based phantom RSUs (PSUs) granted on March 14, 2025.
• A total of 5,944 shares of common stock were disposed of by the Issuer to satisfy tax withholding obligations related to the vested RSUs and PSUs, at a price of $14.2 per share.
• Following these transactions, Stephen D. Griffin beneficially owns 23,963 shares of common stock directly.
• The reporting person also holds 25,649 derivative securities (RSUs) directly, which represent future contingent rights to receive common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports routine executive compensation events (vesting and tax withholding) that are pre-scheduled and do not introduce new material information about the company's operational or financial performance.

Positives

• The vesting of 12,824 restricted stock units (RSUs) and 6,412 performance-based phantom RSUs (PSUs) indicates the achievement of time-based and pre-established performance and strategic targets, respectively.
• The transactions reflect the execution of pre-scheduled executive compensation plans, aligning management's interests with shareholder value over time.

Negatives

• 5,944 shares of common stock were disposed of to cover tax withholding obligations, reducing the direct beneficial ownership of the reporting person.

Future Outlook

The filing indicates that the performance-based phantom RSUs (PSUs) and restricted stock units (RSUs) granted on March 14, 2025, are structured to vest in multiple installments. This transaction represents the first vesting installment, implying future vesting events for the remaining units.

Industry Context

StockSavvy.ai notes that this Form 4 filing details routine executive compensation events, specifically the vesting of equity awards and subsequent tax withholding. Such transactions are standard practice across publicly traded companies in various industries, including healthcare, as a mechanism to incentivize and retain key management personnel.

Comparison to Industry Standards

• The vesting of restricted stock units (RSUs) and performance stock units (PSUs) is a common component of executive compensation packages across the S&P 500, aligning executive incentives with long-term company performance and shareholder value.
• The disposition of shares to cover tax withholding obligations upon vesting is a standard and expected practice for equity compensation, consistent with how executives at companies like Johnson & Johnson or Stryker manage their vested awards.

Stakeholder Impact

• Shareholders: The vesting of equity awards aligns management's long-term interests with shareholder value, as a portion of executive compensation is tied to company performance and stock price.
• Employees: These transactions are part of a standard executive compensation framework, which can influence overall compensation philosophy within the company.

Next Steps

• Future vesting installments of the remaining 25,649 restricted stock units (RSUs) granted on March 14, 2025.
• Future vesting installments of the remaining performance-based phantom RSUs (PSUs) granted on March 14, 2025.

Key Dates

Recommendation

This Form 4 reports routine executive compensation events (vesting of equity awards and subsequent tax withholding) that were pre-scheduled. It does not contain new fundamental information regarding Anika Therapeutics' operational performance, financial outlook, or strategic direction that would warrant a change in an existing investment thesis. Therefore, a 'hold' recommendation is appropriate, as the filing itself does not provide a basis for a 'buy' or 'sell' decision.

Keywords

Anika Therapeutics, ANIK, Form 4, Insider Transaction, Stock Vesting, RSU, PSU, Executive Compensation, Stephen D. Griffin